- Home
- AGEN vs SOL Comparison
AGEN vs SOL Comparison
Compare AGEN & SOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- SOL
- Stock Information
- Founded
- AGEN 1994
- SOL 2005
- Country
- AGEN United States
- SOL United States
- Employees
- AGEN N/A
- SOL N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- SOL Semiconductors
- Sector
- AGEN Health Care
- SOL Technology
- Exchange
- AGEN Nasdaq
- SOL Nasdaq
- Market Cap
- AGEN 38.1M
- SOL 84.6M
- IPO Year
- AGEN 2000
- SOL 2008
- Fundamental
- Price
- AGEN $1.61
- SOL $1.61
- Analyst Decision
- AGEN Buy
- SOL Buy
- Analyst Count
- AGEN 4
- SOL 3
- Target Price
- AGEN $8.00
- SOL $3.50
- AVG Volume (30 Days)
- AGEN 500.1K
- SOL 657.3K
- Earning Date
- AGEN 05-06-2025
- SOL 03-13-2025
- Dividend Yield
- AGEN N/A
- SOL N/A
- EPS Growth
- AGEN N/A
- SOL N/A
- EPS
- AGEN N/A
- SOL N/A
- Revenue
- AGEN $103,463,000.00
- SOL $92,067,000.00
- Revenue This Year
- AGEN $4.03
- SOL N/A
- Revenue Next Year
- AGEN $5.57
- SOL $45.37
- P/E Ratio
- AGEN N/A
- SOL N/A
- Revenue Growth
- AGEN N/A
- SOL N/A
- 52 Week Low
- AGEN $1.44
- SOL $1.04
- 52 Week High
- AGEN $19.69
- SOL $3.00
- Technical
- Relative Strength Index (RSI)
- AGEN 21.45
- SOL 46.44
- Support Level
- AGEN $1.44
- SOL $1.62
- Resistance Level
- AGEN $1.77
- SOL $1.65
- Average True Range (ATR)
- AGEN 0.13
- SOL 0.14
- MACD
- AGEN 0.02
- SOL 0.01
- Stochastic Oscillator
- AGEN 8.00
- SOL 68.42
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has global Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. The company generates maximum revenue from Poland.